{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:42:04Z","timestamp":1789872124935,"version":"4.0.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has emerged as a promising therapy for patients with diabetes, chronic kidney disease, heart failure (HF), or diabetes. We aimed to summarize the current evidence on its cardiovascular (CV) and renal benefits. A systematic search of PubMed, Cochrane CENTRAL, Embase, and ClinicalTrials.gov was conducted up to July 21, 2024. Randomized controlled trials assessing finerenone\u2019s effects on CV and renal outcomes were pooled using a random-effects model, with results expressed as risk ratios (RRs) or mean differences (MDs) with corresponding 95% confidence intervals. Nine randomized controlled trials with 21,731 participants were included. Finerenone significantly reduced all-cause mortality (RR, 0.92;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.03), major adverse CV events (RR, 0.85;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.00001), and HF hospitalizations (RR, 0.82;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.00001). It lowered the risk of sustained \u226557% estimated glomerular filtration rate decline (RR, 0.70;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.01), slowed overall estimated glomerular filtration rate deterioration (MD, \u22121.65;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.02), and reduced urine albumin-to-creatinine ratio (MD, \u22120.28;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.00001). CV death showed a nonsignificant reduction (RR, 0.90;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.05), while myocardial infarction risk (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.37), adverse events (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.40), and discontinuations (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.45) were similar between groups. However, hyperkalemia risk was higher with finerenone (RR, 2.05;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; 0.00001). Finerenone provides significant cardiorenal benefits, reducing CV events, HF hospitalizations, and kidney disease progression in patients with chronic kidney disease, HF, and diabetes, with a favorable safety profile aside from increased hyperkalemia risk. These findings support its role as an effective add-on to standard cardiorenal therapies.\n                  <\/jats:p>","DOI":"10.1097\/crd.0000000000001068","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:00:10Z","timestamp":1761850810000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Finerenone and Its Cardiorenal Protective Effects: A Meta-Analysis of 21,731 Patients From Randomized Trials"],"prefix":"10.1097","author":[{"given":"Bibeka","family":"Rai","sequence":"first","affiliation":[{"name":"From theDepartment of Care of the Elderly, Aneurin Bevan Health Board, Caerleon, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman Farooq","family":"Dar","sequence":"additional","affiliation":[{"name":"Department of General Surgery, County Durham and Darlington National Health Service Foundation Trust, Darlington, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moaz","family":"Alowami","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Libyan International Medical University, Benghazi, Libya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshail Bin","family":"Sajjad","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Sunderland Royal Hospital, Sunderland, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trishtha","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kasturba Medical College, Manipal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Haris","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Head and Neck, South Tyneside and Sunderland NHS Foundation Trust, Tyne and Wear, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman Riaz","family":"Mubarak Ali","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, South Tyneside and Sunderland NHS Foundation Trust, Tyne and Wear, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghuncha","family":"Kamran","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Wexham Park Hospital, Slough, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renju Philip","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Acute Medicine, University Hospitals Plymouth NHS Trust, Derriford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nipun Sanka Bandara Adikari","family":"Mudiyanselage","sequence":"additional","affiliation":[{"name":"Department of Acute Medicine, Ulster Hospital NHS, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"AlQudah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Prince Hamza Hospital, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumna Aziz","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Basildon University Hospital, Nether Mayne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitish","family":"Behary Paray","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Somerset NHS Foundation Trust, Taunton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shahzad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mushood","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National Heart & Lung Institute, Imperial College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"R1-20251030","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","article-title":"Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America.","volume":"29","author":"Bozkurt","year":"2023","journal-title":"J Card Fail"},{"key":"R2-20251030","doi-asserted-by":"crossref","first-page":"107735","DOI":"10.1016\/j.carpath.2025.107735","article-title":"Temporal and demographic disparities in mortality trends for heart failure and COPD-associated heart failure in U.S. Adults: A 1999-2020 analysis of CDC WONDER data.","volume":"77","author":"Ahmed","year":"2025","journal-title":"Cardiovasc Pathol"},{"key":"R3-20251030","doi-asserted-by":"crossref","first-page":"sfaf185","DOI":"10.1093\/ckj\/sfaf185","article-title":"Advanced chronic kidney disease coexisting with heart failure: navigating patients\u2019 management.","volume":"18","author":"Zoccali","year":"2025","journal-title":"Clin Kidney J"},{"key":"R4-20251030","doi-asserted-by":"crossref","first-page":"105919","DOI":"10.4330\/wjc.v17.i5.105919","article-title":"National adult mortality trends due to chronic kidney disease-related atrial fibrillation in the United States from year 2011-2020.","volume":"17","author":"Abdullah Naveed","year":"2025","journal-title":"World J Cardiol"},{"key":"R5-20251030","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12933-021-01408-1","article-title":"Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management.","volume":"20","author":"Ceriello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"R6-20251030","doi-asserted-by":"crossref","first-page":"101882","DOI":"10.1016\/j.jacadv.2025.101882","article-title":"Type 2 diabetes mellitus-related mortality in the United States, 1999 to 2023.","volume":"4","author":"Ahmed","year":"2025","journal-title":"JACC Adv"},{"key":"R7-20251030","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1111\/dom.15181","article-title":"Management of the \u201cwicked\u201d combination of heart failure and chronic kidney disease in the patient with diabetes.","volume":"25","author":"Bell","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"R8-20251030","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities.","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"R9-20251030","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3390\/ijms24032536","article-title":"Benefits of the non-steroidal mineralocorticoid receptor antagonist finerenone in metabolic syndrome-related heart failure with preserved ejection fraction.","volume":"24","author":"Lima-Posada","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R10-20251030","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000958","article-title":"Finerenone\u2019s promise in heart failure and kidney disease.","author":"Shokri","year":"2025","journal-title":"Cardiol Rev"},{"key":"R11-20251030","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"R12-20251030","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes.","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"R13-20251030","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes.","volume":"78","author":"Filippatos","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R14-20251030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes.","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"R15-20251030","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R16-20251030","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R17-20251030","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis.","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"R18-20251030","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial.","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"R19-20251030","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease.","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"R20-20251030","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.","volume":"31","author":"Katayama","year":"2017","journal-title":"J Diabetes Complications"},{"key":"R21-20251030","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"R22-20251030","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease.","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J"},{"key":"R23-20251030","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction.","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"R24-20251030","doi-asserted-by":"crossref","first-page":"e70065","DOI":"10.1002\/clc.70065","article-title":"Cardiovascular efficacy and safety of finerenone: a meta\u2010analysis of randomized controlled trials.","volume":"48","author":"Ahmed","year":"2025","journal-title":"Clin Cardiol"},{"key":"R25-20251030","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-024-07666-x","article-title":"Effect of finerenone in cardiovascular and renal outcomes: a systematic review and meta-analysis.","author":"Rivera-Martinez","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"R26-20251030","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"R27-20251030","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity.","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"key":"R28-20251030","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress.","volume":"9","author":"Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","journal-title":"Front Pharmacol"},{"key":"R29-20251030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling.","volume":"168","author":"Lavall","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"R30-20251030","doi-asserted-by":"crossref","first-page":"e032971","DOI":"10.1161\/JAHA.123.032971","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone improves diastolic dysfunction in preclinical nondiabetic chronic kidney disease.","volume":"13","author":"Lima Posada","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"R31-20251030","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.111.185520","article-title":"Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1.","volume":"59","author":"Nagase","year":"2012","journal-title":"Hypertension"},{"key":"R32-20251030","doi-asserted-by":"crossref","first-page":"e21314","DOI":"10.1096\/fj.202002043RR","article-title":"Antagonistic effects of finerenone and spironolactone on the aldosterone\u2010regulated transcriptome of human kidney cells.","volume":"35","author":"Le Billan","year":"2021","journal-title":"FASEB J"},{"key":"R33-20251030","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s00228-022-03408-w","article-title":"Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials.","volume":"78","author":"Bao","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"R34-20251030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"R35-20251030","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.3390\/jcm12123992","article-title":"Finerenone: questions and answers\u2014the four fundamental arguments on the new-born promising non-steroidal mineralocorticoid receptor antagonist.","volume":"12","author":"Di Lullo","year":"2023","journal-title":"J Clin Med"},{"key":"R36-20251030","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/cvr\/cvad096","article-title":"Cardiorenal interactions in heart failure: insights from recent therapeutic advances.","volume":"120","author":"Damman","year":"2024","journal-title":"Cardiovasc Res"},{"key":"R37-20251030","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes.","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"R38-20251030","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ndt\/gfac157","article-title":"Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.","volume":"38","author":"Ruilope","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"R39-20251030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamacardio.2024.4539","article-title":"Finerenone, serum potassium, and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction.","volume":"10","author":"Vardeny","year":"2025","journal-title":"JAMA Cardiol"},{"key":"R40-20251030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial.","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"R41-20251030","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/ehf2.13219","article-title":"Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice.","volume":"8","author":"Pieronne Deperrois","year":"2021","journal-title":"ESC Heart Fail"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:00:14Z","timestamp":1761850814000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001068","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]}}}